Triazolam
| Triazolam | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 343.20 g/mol [1] |
| Appearance | Tan crystals from 2-propanol [1] |
| Melting point | 233-235 °C [1] |
| Solubility | 4.53 mg/L [1] |
| Predicted LogP | 2.4 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H12Cl2N4 |
| IUPAC name | 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine |
| SMILES | CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl |
| InChI | InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3 |
| InChIKey | JOFWLTCLBGQGBO-UHFFFAOYSA-N |
| CAS number | 28911-01-5 |
| UNII | 1HM943223R |
| PubChem CID | 5556 |
| Pharmacokinetics[] | |
|---|---|
| Onset | 15–30 minutes[3] |
| Elimination half-life | 1.5–5.5 hours |
| Metabolism | Liver |
| Excretion | Kidney |
| Routes of administration | By mouth |
Triazolam (also known as Halcion, Clorazolam, Songar, Novidorm, Triazolamum, U-33,030, Triazolam civ, U-33030, U 33030 or 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine) is a substance of the triazolobenzodiazepine class.
Chemistry
Stereochemistry []
Triazolam is achiral.
Druglikeness
Lipinski's rule of five
Triazolam matches Lipinski's rule of five.Reagents
There are currently 1 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Zimmermann | violet / purple |
Pharmacology
ATC Classification
- nervous system (N)
- psycholeptics (N05)
- hypnotics and sedatives (N05C)
- benzodiazepine derivatives (N05CD)
- (N05CD05)
- triazolam (N05CD05)
MeSH Classification
Mechanism of action []
Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| CYP3A4 | induction / metabolism / inhibition | 192 (40 contraindicated) |
|---|---|---|
| GABRA1 | shared target | 33 |
| GABRA2 | shared target | 31 |
| GABRA3 | shared target | 31 |
| GABRA4 | shared target | 31 |
| GABRA5 | shared target | 31 |
| GABRA6 | shared target | 31 |
| GABRB1 | shared target | 31 |
| GABRB2 | shared target | 31 |
| GABRB3 | shared target | 31 |
| GABRD | shared target | 31 |
| GABRE | shared target | 31 |
| GABRG1 | shared target | 31 |
| GABRG2 | shared target | 31 |
| GABRG3 | shared target | 31 |
| GABRP | shared target | 31 |
| GABRQ | shared target | 31 |
Medical side effects []
94 side effects listed on drug labels in SIDER 4.1 (triazolam).
- Somnolence
- Headache
- Dizziness
- Lightheadedness
- Syncope
- Nervousness
- Tension
- Ataxia
- Nausea
- Vomiting
- Coordination abnormal
- Abdominal pain
- Gastrointestinal pain
- Aggression
- Amnesia
- Decreased appetite
- Anxiety
- Asthenia
- Fatigue
- Chest pain
- Confusional state
- Feeling abnormal
- Malaise
- Constipation
- Delusion
- Depersonalisation
- Dermatitis
- Diarrhoea
- Drug abuse
- Dysarthria
- Slurred speech
- Osteoarthritis
- Dysgeusia
- Dyspnoea
- Oedema
- Flatulence
- Glossitis
- Hallucination
- Hypersensitivity
- Hypertension
- Incontinence
- Irritability
- Jaundice
- Muscle spasms
- Muscle spasticity
- Nightmare
- Pain
- Palpitations
- Paraesthesia
- Pruritus
- Respiratory tract infection
- Sleep disorder
- Somnambulism
- Stomatitis
- Mouth irritation
- Shock
- Loss of consciousness
- Tachycardia
- Tinnitus
- Tremor
- Dry mouth
- Urinary retention
- Hepatic failure
- Agitation
- Mood swings
- Affect lability
- Drug withdrawal syndrome
- Depressed level of consciousness
- Consciousness clouding
- Muscular weakness
- Menstruation irregular
- Discomfort
- Ill-defined disorder
- Disorientation
- Thinking abnormal
- Mental disability
- Derealisation
- Memory impairment
- Anterograde amnesia
- Euphoric mood
- Eye irritation
- Glossodynia
- Dysuria
- Strangury
- Erythema
- Mania
- Dysaesthesia
- Insomnia
- Visual impairment
- Sexual dysfunction
- Hyperhidrosis
- Muscle tone disorder
- Deafness
- Hearing impaired
Indications
- Insomnia
Subjective effects []
Experience reports
Legal status []
- Australia: Triazolam is a Schedule 4.
- Brazil: Triazolam is a B1.[4]
- Canada: Triazolam is a Schedule IV.
- Germany: Triazolam is Prescription only/Anlage III.
- New Zealand: Triazolam is a Class C5 (discontinued).
- United Kingdom: Triazolam is a Class C under the "Misuse of Drugs Act 1971".
- United States: Triazolam is a Schedule IV under the "Controlled Substances Act".
- United Nations: Triazolam is a Schedule IV narcotic under the "Single Convention on Narcotic Drugs 1961".
- Other: Triazolam is a SE: Förteckning IV, In general: ℞ (Prescription only).[5]
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5556, Triazolam. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5556
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Triazolam. UNII: 1HM943223R. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/1HM943223R
What Is Triazolam Used For?. www.icliniq.com. 1 November 2022. https://www.icliniq.com/articles/drug-and-supplements/triazolam
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. Läkemedelsverket. https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/lvfs/lvfs-2011-10-konsoliderad.pdf
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 15:29:18 |
| drugspro | ok | 2026-11-20 15:29:14 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 15:29:14 |
| gsrs | ok | 2026-11-20 15:29:15 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015034) | 2026-11-20 15:29:14 |
| kegg | ok | 2026-11-20 15:29:17 |
| pubchem | ok | 2026-11-20 15:29:13 |
| ok | 2026-11-20 15:29:14 | |
| sider | ok | 2026-11-20 15:29:14 |
| structure | ok | 2026-11-20 15:29:14 |
| wikipedia | ok | 2026-11-20 15:29:14 |